 |
市場調查報告書
全球裘馨氏肌肉萎縮症(DMD)治療市場:各治療方法、治療類型、終端用戶、地區(2018年∼2023年)Duchenne Muscular Dystrophy Treatment Market - Growth, Trends, and Forecast (2019 - 2024) |
||||||
| 出版商 | Mordor Intelligence LLP | 商品編碼 | 704957 | ||||
| 出版日期 | 內容資訊 | 英文 115 Pages 商品交期: 2-3個工作天內 |
|||||
| 價格 |
|
||||||
| 全球裘馨氏肌肉萎縮症(DMD)治療市場:各治療方法、治療類型、終端用戶、地區(2018年∼2023年) Duchenne Muscular Dystrophy Treatment Market - Growth, Trends, and Forecast (2019 - 2024) | ||
| 出版日期: 2019年02月01日 | 內容資訊: 英文 115 Pages |
|
全球裘馨氏肌肉萎縮症(DMD)治療市場，預計從2018年到2023年的整個預測期內以超越40％的年複合成長率發展。
本報告提供全球裘馨氏肌肉萎縮症(DMD)治療市場調查，各治療方法、治療藥類型、終端用戶、地區的市場規模的變化與預測，市場趨勢，市場成長要素及阻礙因素分析，競爭情形，主要企業的簡介等全面性資訊。
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
The propelling factors for the growth of the Duchenne muscular dystrophy (DMD) treatment market include the rising disease burden of Duchenne muscular dystrophy, increasing investments in biopharmaceutical R&D to release novel disease therapies, and increasing awareness campaigns for DMD.
Currently, there is an increase in the number of clinical trials for testing the future treatment for Duchenne muscular dystrophy. The only accepted pharmacological therapy for the treatment of DMD is corticosteroid-based anti-inflammatory treatment.
The rising prevalence of chronic diseases, such as cardiovascular and neurovascular diseases, and arthritis, and increasing healthcare insurance coverage are the major factors likely to accelerate the growth of the market. The pharmaceutical drug discovery and development have also grown rapidly in the past few years. As there have been great breakthroughs in technology in the last few years that may facilitate research processes and as the explosion of science in understanding the causes of diseases has made target selection more rational than ever, almost all major companies are now concentrating on R&D, which is likely to have a major impact on the market in the coming years.
Furthermore, with increasing awareness among people and with the government's urgency for the treatment of the disease, there is a big opportunity for the companies to conduct their trails and for new drugs launches, due to which, the market is expected to grow in the coming years.
As per the scope of the report, Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It is a rare muscle disease, which majorly affects males. There are novel drugs and therapies, disease-modifying, and mutation-specific therapies that are some of the emerging major breakthroughs in the DMD treatment market.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Segment is Expected to Grow Fastest During the Forecast Period
Corticosteroids are the only known pharmacological treatment for DMD and help to suppress muscle inflammation. This treatment is being limited by its inadequate therapeutic efficacy, and considerable side effects, and hence, non-steroidal anti-inflammatory drugs (NSAIDs) can be used to reduce the inflammation of muscles. The nonsteroidal anti-inflammatory drugs are expected to witness a CAGR of 49.2% over the forecast period.
However, other therapies and treatments include stem cell therapy, repurposing drugs, anti-fibrotics, myostatin inhibition, gene editing (CRISPR/Cas9), etc. Currently, prednisone/prednisolone and deflazacort have been used for the treatment of Duchenne muscular dystrophy, which is expected to drive the growth of the market, over the forecast period.
North American Region holds the Largest Market Share of the Market Currently and is Believed to Follow the Same Trend Over the Forecast Period
North America dominates the global Duchenne muscular dystrophy market, due to new product innovations, high healthcare expenditure, and government awareness programs. The United States has dominated the regional market and is projected to maintain its lead, owing to the rising disease incidence and anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with the increasing clinical trials around the world, especially in the United States and Europe.
With increasing campaigns and awareness programs, the number of patients is expected to come down, and hence, many companies are conducting campaign programs that help to improve focus on medicines for DMD treatment. There are also very few companies for new drug research for rare diseases because it needs bigger funds. Therefore, the market is not well established in many other therapeutic areas. However, it is expected to experience high growth and expand during the forecast period.
